Immune deficiencies, infection, and systemic immune disordersB-cell reconstitution after lentiviral vector–mediated gene therapy in patients with Wiskott-Aldrich syndrome
Key words
Abbreviations used
Cited by (0)
Supported by Telethon (TIGET Core grant A2 to A.V.), Ministero della Salute (RF 2009 Giovani Ricercatori Grant, to M.v.d.B.), EU project CELL PID (FP7 no. 261387 to A.A. and A.V.). M.v.d.B. is supported by the Dutch Scientific organization (ZonMW Vidi grant no. 016.126.323). L.S. conducted this study as partial fulfillment of her PhD in Molecular Medicine, Program in Basic and Applied Immunology, San Raffaele University, Milan, Italy. Since January 2014, GlaxoSmithKline has in-licensed the WAS gene therapy program and has become the financial sponsor of the clinical trial conducted at TIGET.
Disclosure of potential conflict of interest: This work was supported by Telethon (TIGET Core grant A2 to A.V.), Ministero della Salute (RF 2009 Giovani Ricercatori Grant), and EU project CELL PID (FP7 no. 261387). L. Sereni conducted this study as partial fulfillment of her PhD in Molecular Medicine, Program in Basic and Applied Immunology, San Raffaele University, Milan, Italy. M. van der Burg is supported by Dutch Scientific organization (ZonMW Vidi grant 016.126.323). Since January 2014, GlaxoSmithKline has in-licensed the WAS gene therapy program and has become the financial sponsor of the clinical trial conducted at TIGET. M. H. Albert has received stock options from Amgen and JUNO Pharmaceuticals. The authors declare that they have no other relevant conflicts of interest.